Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non-small cell lung cancer and small cell lung cancer

Journal of Cellular Biochemistry

Volumn 62, Issue SUPPL. 24, 1996, Pages 173-185

  Shaw, Gail L ^a   Gazdar, Adi F ^b   Phelps, Ruby ^c   Steinberg, Seth M ^c   Linnoila, R Ilona ^c   Johnson, Bruce E ^c   Oie, Herbert K ^c   Russell, Edward K ^c   Ghosh, Bimal C ^d   Pass, Harvey I ^c   Minna, John D ^b   Mulshine, James L ^c   Ihde, Daniel C ^e  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cell survival; drug resistance; non small cell lung cancer; small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT; CARMUSTINE; CAV PROTOCOL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LOMUSTINE; METHOTREXATE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; DOSE RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INDIVIDUALIZATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; SCREENING; TREATMENT OUTCOME; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EVALUATION; LABORATORY DIAGNOSIS; LUNG TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SMALL CELL CARCINOMA; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; EVALUATION STUDIES; HUMANS; LOMUSTINE; LUNG NEOPLASMS; MECHLORETHAMINE; METHOTREXATE; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SPECIMEN HANDLING; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 33646962800     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.240630513     Document Type: Article

References (34)

1. Mulshine JL, Glatstein E, Ruckdeschel JC (1986): Treatment of non-small cell lung cancer. J Clin Oncol 4:1704-1715.
2. Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD (1984): Small cell lung cancer 1973-1983: Early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10:515-39.
3. Johnson DH, Greco FA (1986): Small cell carcinoma of the lung. CRC Crit Rev Oncol Hematol 4:303-336.
4. Carney DN, Broder L, Edelstein M, Gazdar AF, Hansen M, Havemann K, Matthews MJ, Sorenson GD, Videlov, L (1983): Experimental studies of the biology of human small cell lung cancer. Cancer Treat Rep 67:27-35.
5. Carney DN, Gazdar AF, Cuttitta F, et al. (1984): In vitro studies of the biology of lung cancer. In Mizell M, Correa P (eds): "Lung Cancer: Causes and Prevention." Deerfield Beach, FL: Verlag Chemie Int., pp 247-261.
6. Gazdar AF, Carney DN, Nau M (1985): Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res 45:2924-2930.
7. Simms E, Gazdar AF, Abrams PG, Minna JD (1980): Growth of human small cell (oat cell) carcinoma of the lung in serum-free growth factor-supplemented medium. Cancer Res 40:4356-4363.
8. Carney DN, Gazdar AF, Bepler C, et al. (1985): Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 45:2913-2923.
9. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, Cotelingam JD, Johnson BE, Minna JD, Ihde DC (1990): Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: A prospective clinical trial. J Natl Cancer Inst 82:117-124.
10. Ihde DC, Deisseroth AB, Lichter AS, Bunn PA, Carney DN, Cohen MH, Veach SR, Makuch RW, Johnston-Early A, Abrams RA, et al. (1986): Late intensive combined modality therapy followed fay autologous bone marrow infusion in extensive-stage small-cell lung cancer. J Clin Oncol 4:1443-54.
11. Beahrs OH, Henson DE, Hutter RVP, Myers MH (eds) (1988): American Joint Committee on Cancer. "Manual for Staging of Cancer," 3rd ed. Philadelphia, PA: J.B. Lippincott Co., pp 115-121.
12. Baylin SB, Stevens SA, Shakir KM (1978): Association of diamine oxidase and ornithine decarboxylase with maturing cells in rapidly proliferating epithelium. Biochem Biophys Acta 541:415-419.
13. 14C]carboxyl-labeled amino acids. Anal Biochem 84:638-641.
14. Longeval E, Klastersky J (1982): Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium). Cancer 50:2751-2756.
15. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S (1986): A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14-22.
16. Mulshine J, Ihde D, Linnoila RI, Veach S, Steinberg S, Woods E, Phelps R, Minna J, Gazdar A ( 1987): Preliminary report of a prospective trial of neuroendocrine marker analysis in in vitro drug sensitivity testing in patients with non-small cell lung cancer (Abstract 713). Proc Am Soc Clin Oncol 6:181.
17. Stevenson H, Gazdar AF, Phelps R, Linnoila RI, Ihde DC, Ghosh B, Walsh T, Woods EL, Oie H, O'Connor T, Makueh R, Kramer BS, Mulshine JL (1990): Tumor cell lines established in vitro: An independent prognostic factor for survival in non-small cell lung cancer. Ann Intern Med 113:764-770.
18. Shaw GL, Gazdar AF, Phelps R, Linnoila RI, Ihde DC, Johnson BE, Oie HK, Pass HI, Steinberg SM, Walsh T, Ghosh BC, Nesbitt JC, Cotelingam JD, Minna JD, Mulshine JL (1993): Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res., 53: 5181-5187.
19. Hammond ME, Sause WT (1985): large cell neuroendocrine tumors of the lung: Clinical significance and histological definition. Cancer, 56:1624-1629.
20. McDowell EM, Wilson TS, Trump BF (1981): Atypical neuroendocrine tumors of the lung. Arch Pathol Lab Med 105:20-28.
21. Gazdar AF, Kadoyama C, Venzon D, Park J-G, Tsai C-M, Linnoila RI, Mulshine JL, Ihde DC, Giaccone G (1992): Association between histologic type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Mongr 13:191-196.
22. Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD (1986): Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 46:798-806.
23. Gazdar AF, Oie HK (1986): Correspondence regarding growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum free defined medium (letter). Cancer Res 46:6011.
24. Ervin TJ, Beckett MA, Miller D, Rheinwald JG (1982): Clonal growth and serial passage of head and neck squamous cell carcinoma: Tumor site determines cultivability (Abstract C-759). Proc Am Soc Clin Oncol 1:195.
25. Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PA Jr, Guccion JG, Minna JD (1980): Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res 40: 3502-7.
26. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK (1983): A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res 43:749-757.
27. Weisenthal LM, Dill PL, Kurnick NB, Lippman ME (1983): Comparison of dye exclusion assays with a clonogenic assay in determination of drug-induced cytotoxicity. Cancer Res 43:258-264.
28. Weisenthal LM, Nagourney RA, Kern DH, Boullier B, Bosanquet AG, Dill PL, Messenger JC, Moran EM (1989): Approach to the clinical circumvention of drug resistance utilizing a non-clonogenic in vitro assay measuring the effects of drugs, radiation, and interleukin II on largely non-dividing cells. In D. Amadori (ed): "Adv Clin Oncol," Vol. 1. Pavia, Italy: Edimes, pp 91-111.
29. Mehta CR, Patel NR (1983): A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 78:427-434.
30. Kaplan EL, Meier P (1958): Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
31. Mantel N (1966): Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chem Rep 50:163-170.
32. Gazdar AF, Linnoila RI (1988): The pathology of lung cancer: Changing concepts and newer diagnostic techniques. Semin Oncol 15:215-225.
33. Fleiss JL (1986): "The Design and Analysis of Clinical Experiments." New York: Wiley.
34. Stevenson HC, Gazdar AF, Linnoila RI, Russell EK, Oie HK, Steinberg SM, Ihde DC (1989): Lack of relationship between in vitro tumor cell growth and prognosis in extensive-stage small-cell lung cancer. J Clin Oncol 7:923-931.